Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis.

@article{Aso2007PlasminogenAI,
  title={Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis.},
  author={Yoshimasa Aso},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2007},
  volume={12},
  pages={
          2957-66
        }
}
  • Y. Aso
  • Published 1 May 2007
  • Biology, Medicine
  • Frontiers in bioscience : a journal and virtual library
Impaired fibrinolysis may be associated with development of atherothrombotic cardiovascular disease (CVD) in metabolic syndrome or type 2 diabetes. Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of fibrinolysis, is elevated in a number of clinical situations that are associated with high incidence of CVD. Impaired fibrinolysis resulting from high plasma PAI-1 can lead to excessive fibrin accumulation within vessels, resulting in atherothrombosis. Increased expression of PAI… 
View on PubMed
bioscience.org
129 Citations
Highly Influential Citations
7
Background Citations
63
Results Citations
3

129 Citations

Citation Type

Citation Type

Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases
TLDR
PAI-1 has become recognized as a central molecule linking pathogenesis and progression of thrombotic vascular events including stroke and plays diverse roles in metabolic and vascular disease and may participate in the evolution of brain damage and recovery after stroke.
Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases
TLDR
Pathologically, the PAI-1 inhibitor improved histological remodeling of myocardium and arteries with suppression of inflammation and thrombus formation and more research is needed to further elucidate the association between PAi-1 expression and cardiovascular disease.
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.
TLDR
Despite some controversial and unclear issues, PAI-1 represents an extremely promising marker that may become a biological parameter to be progressively considered in the prognostic evaluation, in the disease monitoring, and as treatment target of age-related conditions in the future.
PAI-1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients.
TLDR
The study demonstrated a close direct relationship between TNF-α and PAI-1, a potent inhibitor of plasminogen activation and fibrinolysis in obese patients with and without coronary artery disease.
Plasminogen Activator Inhibitor 1 in Platelets - Studies of Synthesis, Activity, and Glycosylation Patterns
TLDR
The role of platelets in inhibition of fibrinolysis, and in particular the physiological regulation of platelet-derived PAI-1; its synthesis, activity, and potential contribution to plasma levels is investigated to clarify the previous irreconcilable findings.
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs.
The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis
TLDR
The components and diverse functions of the PA system in physiology and its importance in angioedema pathogenesis are presented.
PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target
TLDR
The review offers up-to-date knowledge on the mechanisms of action of PAI-1 together with the role of altering protein function to improve hypofirbinolysis and may form for the basis of future new class of antithrombotic agents that reduce vascular complications in diabetes.
Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells.
TLDR
The results suggest that LOX-1, H-Ras, and Raf-1/ERK1/2 are implicated in PAI-1 expression induced by oxidized LDLs or LDL in cultured EC.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 127 REFERENCES
Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
TLDR
Whether PAI-1 secretion is or is not sensitive to the prevailing concentration of glucose in the conditioned medium of endothelial and liver cells, which are thought to be the major sources of circulating PAI -1 in vivo, is determined.
Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects
TLDR
Evidence is provided that diabetes is associated with increased PAI-1 in the arterial wall, which might be an important factor for increased cardiovascular risk and unfavorable plaque evolution in diabetes.
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.
TLDR
Examination of the expression of PAI-1 mRNA in segments of 11 severely diseased and 5 relatively normal human arteries obtained from 16 different patients undergoing reconstructive surgery for aortic occlusive or aneurysmal disease provides initial evidence for the increased expression and suggests a role for PAi-1 in the progression of human atherosclerotic disease.
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries.
TLDR
The increased synthesis of PAi-1 by cellular components of the atherosclerotic plaque and the extracellular accumulation of PAI-1 may contribute to the thrombotic complications associated with plaque rupture and possibly play a role in the accumulation ofextracellular matrix deposits.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
TLDR
The disproportionate elevation of PAi-1 compared with u-PA observed in atheromatous material extracted from vessels of diabetic subjects is consistent with increased gene expression of PAI-1 in vessels as well as the known increase ofPAI- 1 in blood, presumably reflecting increased synthesis.
Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.
TLDR
It is suggested that hyperinsulinemia attributable to augmented concentrations of proinsulin and insulin in plasma increase plasma PAI-1 activity and may contribute to acceleration of atherosclerosis and impairment of coronary thrombolysis in patients with NIDDM.
Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk
TLDR
The clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link and proinflammatory cytokines might regulate PAI‐1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans.
Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
TLDR
Impaired fibrinolysis in obesity is probably also due to an increased expression of PAI-1 in adipose tissue, and an altered function of the endocrine system and an impaired auto-/paracrine function at the fat cell levels may mediate this disturbance of the fibrinoslytic system and thereby increase the risk for cardiovascular disease.
Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
Plasminogen activator system in human coronary atherosclerosis.
TLDR
Altered coronary artery expression of plasminogen activator (PA) system components may predispose to thrombosis and modulate the vascular response to injury, and coronary arteries with a wide range of vascular pathology express an abundance of antifibrinolytic potential with enhanced local expression of profibrinoslytic proteins, mainly within atherosclerotic plaques.
...
1
2
3
4
5
...